skip to main content

    Updated Visitor Guidelines

 

MENU

 

Acute Leukemia

New study finds disturbing lack of key leukemia medication

New research finds fewer than one-third of hospitals had immediate availability of a crucial blood cancer medication called all-trans retinoic acid (ATRA). ATRA is initiated early in the treatment of acute promyelocytic leukemia to prevent major bleeding, clotting and potential death.

U-M Rogel Cancer Center first in Michigan to offer all FDA approved CAR T-cell therapies

Media contact: Jessica Webster-Sendra, 734-764-2220 |  Patients may contact Cancer AnswerLine, 800-865-1125

ANN ARBOR, Michigan — With the recently announced FDA approval of Kymriah to treat adults with lymphoma, the University of Michigan Rogel Cancer Center is the first center in Michigan to offer all currently available CAR T-cell therapies.

Revised understanding of graft-versus-host disease origins offers new direction for potential therapies

An international research team led by the University of Michigan Life Sciences Institute is changing the understanding of the key cellular and molecular events that trigger graft-versus-host disease, an often-fatal complication of bone marrow transplants.

Researchers develop new potential drug for rare leukemia

Researchers have developed a new drug candidate that shows potential in laboratory studies against a rare type of acute leukemia. And additional studies suggest the same compound could play a role in prostate cancer treatment as well.